Dorsavi Ltd. · ASX:DVL

Dorsavi — Investor Presentation (September 2014)

46 slides from Dorsavi's investor presentation, Sep 9, 2014

  1. Slide 1: dorsaVi September 2014

    For personal use only September 2014 www.dorsavi.com 1 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  2. Slide 2: Introduction

    Introduction For personal use only World first technology using sensors to capture and assess dorsaVi Limited ASX:dvl human movement, enabling many aspects of detailed Share price $0.40 (issue price 40 human movement and position to be accurately captured, cents) quantified and assessed outside a bi

  3. Slide 3: Highly experienced global team

    Highly experience global team For personal use only SLIDE TITLE | 3 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  4. Slide 4: Board of Directors

    Board of Directors For personal use only Chairman, Herb Elliott AC MBE Non Executive Director, Olympic Gold Medallist (Rome 1960), Michael Panaccio BSc (Hons), MBA, PhD Deputy Chairman of Fortescue Metals FAICD Group Limited; Former Director of Ansell, Co-founder of Starfish Ventures, Director Forme

  5. Slide 5: Major Goal to Build a Global Team - New staff

    Major Goal to Build a Global Team - New staff Australia Europe United States For personal use only Chief Marketing Officer Jerome Whelan Mark Heaysman Zoe Whyatt Tom Doe John Kowalczyk Final Stages CFO OH&S Leader COO Europe Clinical & Sports Specialist President of dorsaVi US CMO National Sales Man

  6. Slide 6: Activity update

    Activity update For personal use only 27th Mar Allianz and dorsaVi partner to improve workplace safety 8th Apr John Kowalczyk announced to lead US operations 7th May Jerome Whelan appointed as dorsaVi CFO 4th Jul dorsaVi acquires AWC for strategic access to OH&S market 8th Jul 3rd English Premier Le

  7. Slide 7: Revolutionary technology

    Revolutionary technology For personal use only • Wearable sensors that measure movement and muscle activity • High quality analysis from multiple areas of the body Recording Device Muscle Activity Sensor • Surface EMG to capture muscle activity of relevant muscles Movement Sensor • 3D Acc, Gyro & ma

  8. Slide 8: Movement Technologies

    Movement Technologies For personal use only Consumer Products Data at low rates (4-10Hz) $150 - $400 purchase price Simple data (calories, steps/day, sleep position) No reference to normal data Low validity of movement data Single sensor unit Number of devices in the market Nike+ Pod & GPS monitor L

  9. Slide 9: Movement Technologies

    Movement Technologies For personal use only Consumer Products Data at low rates (4-10Hz) $150 - $400 purchase price Simple data (calories, steps/day, sleep position) No reference to normal data Low validity of movement data Single sensor unit Number of Z Flo+ devices in Hawk the market Raptor Vicon

  10. Slide 10: Movement Technologies: The Opportunity

    Movement Technologies For personal use only Consumer Products Data at low rates (4-10Hz) $150 - $400 purchase price Simple data (calories, steps/day, sleep position) No reference to normal data Low validity of movement data dorsaVi Single sensor unit Number of devices in The the market Opportunity L

  11. Slide 11: Who wants this data? The Professionals do

    Who wants this data? The Professionals do For personal use only 1. Human Eye 2. Video and 3. Movement Dartfish Lab Subjective Long time to Time consuming analyse Long time to train Errors with Expensive analysis Open to debate 1D only Artificial setting “People don’t come to Mayo for my eyes. People

  12. Slide 12: dorsaVi: High quality, immediate and intuitive

    dorsaVi: High quality, immediate and intuitive For personal use only 1. Human Eye dorsaVi What the professionals want: • High quality accurate data Subjective • Test what is important • Comparison to normal Long time to train • Immediate and intuitive reports Open to debate 12 Copyright dorsaVi Ltd

  13. Slide 13: Fundamental applications of the system

    Fundamental applications of the system For personal use only A Current Affair video removed. Will be added back in Live Assessment Monitoring Bio feedback Live training Measurement Training/Treatment 13 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  14. Slide 14: dorsaVi has three ground breaking products

    dorsaVi has three ground breaking products: For personal use only 14 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  15. Slide 15: For personal use only

    For personal use only 15 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  16. Slide 16: Every sport has a different movement signature

    Every sport has a different movement signature Australian clients For personal use only New customer International clients 16 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  17. Slide 17: Early US traction

    Early US traction For personal use only United States – Initial sites using ViPerform 17 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  18. Slide 18: How groups are using ViPerform

    How groups are using ViPerform For personal use only Knee In The Gym Assessment Hamstring Live Training 18 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  19. Slide 19: Knee Control Test - Left leg

    Knee Control Test - Left leg For personal use only 19 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  20. Slide 20: Knee Control Test - Right leg

    Knee Control Test - Right leg For personal use only 20 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  21. Slide 21: Competitors in the Wearable Sensor Space

    Competitors in the Wearable Sensor Space • For personal use only There are a number of wearable sensor groups producing low to medium quality data • Many single sensor systems with little validation and minimal clinical trial data “If you want to bring reliability and objectivity to movement assessm

  22. Slide 22: For personal use only

    For personal use only 22 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  23. Slide 23: Clinical

    Clinical For personal use only 23 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  24. Slide 24: Clinical Market

    Clinical Market For personal use only Clinically validated • Clinical trial undertaken at 8 sites including the Austin and Epworth Hospitals. • 112 subject Randomised Controlled Trial with 54 (p<0.001) control and 58 intervention subjects. • Significant and sustained results at 52 weeks for both red

  25. Slide 25: Protocol Based Treatment

    Protocol Based Treatment For personal use only Medical Physio Assessment Treatment Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 Week 12 3 Medical & 8 Allied Health sessions over 12 weeks Standardised report provides common language 25 Copyright dorsaVi Ltd 2014. Commercial

  26. Slide 26: Clinics leading the way using ViMove

    Clinics leading the way using ViMove For personal use only 26 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  27. Slide 27: Growth of applications in the clinical market

    Growth of applications in the clinical market For personal use only Lower Hip & Knee Hamstring Gym Running Rowing Cervical back Groin Reasons people see a physiotherapist • Low back pain – 33% • Knee – 13% • Shoulder – 12% • Neck – 10% Applicable to over 75% • Hip – 8% over conditions treated 27 Cop

  28. Slide 28: Close to 10,000 datasets and growing daily

    Close to 10,000 datasets and growing daily For personal use only 28 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  29. Slide 29: Scale Up for the Clinical Market

    Scale Up for the Clinical Market For personal use only • Public awareness campaigns Marketing • Existing high profile clients • KOLs speaking at local & international conferences • Charging more per session Earning Potential • Passive income • Additional tests Increasing Value • Exercises on the web

  30. Slide 30: dorsaVi's Global Strategic Initiatives

    dorsaVi’s Global Strategic Initiatives For personal use only Research – Clinical Trials • Guide clinical research projects in line with dorsaVi goals Reimbursement • Identify existing item codes that fit ViMove uses Education • Educate the next generation of clinicians Engage Market • KOLs, Conferen

  31. Slide 31: OH&S and Compliance

    For personal use only OH&S and Compliance 31 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  32. Slide 32: OH&S Unique Offering to Large Corporates

    OH&S Unique Offering to Large Corporates For personal use only • Assess workplace systems • Assess work tasks & environments • Quality Management Systems • Better decision making based on • Workplace safety controls evidence • Develop and test solutions for safety and productivity 32 Copyright dorsa

  33. Slide 33: OH&S Clients

    OH&S Clients For personal use only 33 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  34. Slide 34: Why this offering resonates with Large Corporates

    Why this offering resonates with Large Corporates For personal use only • Audit QMS and work practices to identify problems or potential problems • Build & Maintain an appropriate Quality Management System (QMS) • Understand and pin point any Manual Handling risk • Find solutions to reduce or elimin

  35. Slide 35: Australian Workplace Compliance

    Australian Workplace Compliance For personal use only • Audits, WorkSafe guidelines & • Audits and gaps analysis: AS/NZS 4801 standards AS/NZS 4801, OHSAS 1800a and • Compliance recommendations ISO 9001 & action plans • Compliance recommendations • Risk and priority rating & action plans • Implement

  36. Slide 36: Taking the guess work out of workplace change

    Taking the guess work out of workplace change For personal use only 1. Understand problem from client • Reduce injuries & costs 5. Implement 2. Measure Solution Baseline data • Improve productivity • Build a positive safety culture Feedback loops 4. Test the 3. Design Potential Solutions to Solution

  37. Slide 37: OH&S

    OH&S For personal use only 37 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  38. Slide 38: New Modules

    New Modules • Denmark – Cervical Spine application For personal use only • Product of choice from leading Denmark Uni • Assessment & Biofeedback in RCT • To be used in Cervical radiculopathy trial • Ideal for Clinical and OH&S market • US – Knee prevention application • Collaborating with leading S&

  39. Slide 39: dorsaVi working with leading research groups

    dorsaVi working with leading research groups For personal use only 39 Golf paper from Griffith University Copyright dorsaVi Ltd 2014. Commercial in Confidence

  40. Slide 40: The Consumer

    The Consumer Consumer For personal use only market Medical Elite Sports OH&S 40 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  41. Slide 41: Options for the consumer market

    Options for the consumer market For personal use only • Four clear options for the consumer market • Running is the perfect example of high quality algorithm for consumer space • Optimise for the consumer market and align with the right partner Running Cycling Golf Gym/Pilates 41 Copyright dorsaVi L

  42. Slide 42: ViRun: The first step into the consumer market

    ViRun: The first step into the consumer market For personal use only 42 Copyright dorsaVi Ltd 2014. Commercial in Confidence

  43. Slide 43: dorsaVi's Priority Markets & International Launch

    dorsaVi’s Priority Markets & International Launch For personal use only UK, Germany and Scandinavia USA UK: - 50,000 Physios Germany: - 128,000 Physios - 52,000 Med centres US: - 284,000 Physios - 661,000 Physicians Sports – High Priority Clinical – High Priority Test Market - 24,000 Physios - 25,00

  44. Slide 44: Business model and pricing

    Business model and pricing For personal use only Business Model for ViMove and ViPerform • Licence model $5,000 – 7,500 p.a. per unit + consumables • Value add with personalised web-based exercises • Annuity based Business Model for ViSafe & AWC • Project based fee and annuity for AWC work • AWC con

  45. Slide 45: Financial Summary

    Financial Summary For personal use only 2011 2012 2013 2014 Revenue 65,368 244,471 398,607 767,031 EBITDA (903,107) (2,332,015) (2,148,749) (3,852,593) Loss from continuing (489,409) (1,510,166) (1,659,235) (3,562,024) operations Cash position $13.97M • Increase marketing using high profile clients

  46. Slide 46: News Flow

    News Flow For personal use only Next 12 months Numerous major industry conference presentations New OH&S contracts with large Australian & International companies Partnership with major insurers Additional Australian / UK Elite Sports sign ups Build revenue in US clinical market (Physicians and Phys

dorsaVi — Investor Presentation (September 2014) on 6ix